Table 2.
Studies on the incidence of CRS of different grades and the classification criteria
| Disease/Target antigen | Costimulatory domain | CRS classification criteria | CRS percentage (severe rate) | Reference |
|---|---|---|---|---|
| ALL | ||||
| CD19 | 4-1BB | Consensus criteria and NCI CTCAE v4.03 | 70% (G3–5: 12%) | Hay et al. (2017)34 |
| CD19 | CD28 | NCI consensus CRS grading system and NCI CTCAE v4.03 | 80% (G3-4: 16%) | Curran et al. (2019)36 |
| CD19 | CD28 | Modified criteria of Lee and colleagues35 and NCI CTCAE v4.02 | 76% (G3-4: 28%) | Lee et al. (2015)37 |
| CD19 | 4-1BB | 77% (G3-4: 47%) | Maude et al. (2018)38 | |
| CD19 | CD28 | MSKCC CRS grading system and NCI CTCAE v4.03 | 85% (G3-4: 26%) | Park et al. (2018)44 |
| CD19 | 4-1BB | Modified criteria of Lee and colleagues and NCI CTCAE v4.03 | 66.7% (G3-4: 40%) | Hu et al. (2017)45 |
| CD22 | 4-1BB | 76% | Fry et al. (2018)39 | |
| Lymphoma | ||||
| CD19 | CD28 | Modified criteria of Lee and colleagues and NCI CTCAE v4.03 | 92% (G3-4: 11%) | Locke et al. (2019)40 |
| CD19 | 4-1BB | University of Pennsylvania grading scale and NCI CTCAE v4.03 | 58% (G3-4: 22%) | Schuster et al. (2019)8 |
| Multiple myeloma | ||||
| BCMA | 4-1BB | Modified criteria of Lee and colleagues and NCI CTCAE v4.03 | 90% (G3-4: 7%) | Zhao et al. (2018)195 |
| BCMA | 4-1BB | Modified criteria of Lee and colleagues and NCI CTCAE v4.03 | 76% (G3-4: 6%) | Raje et al. (2019)42 |
| CD19 & BCMA | 4-BB & 4-1BB | Modified criteria of Lee and colleagues and NCI CTCAE v4.03 | 90% (G3-4: 5%) | Yan et al. (2019)43 |
| CLL | ||||
| CD19 | 4-1BB | Consensus criteria and NCI CTCAE v4.03 | 70% (G3-5: 12%) | Hay et al. (2017)34 |
CRS grading is performed using the classification proposed by Lee and his colleagues, while grading of organ toxicities is performed according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03